University of Pennsylvania (Site 1031), 3400 Spruce Street — Philadelphia, Pennsylvania

University of Pennsylvania (Site 1031), 3400 Spruce Street is a clinical research site located in Philadelphia, Pennsylvania, United States 19104.

Crixeo Clinical Trials Trust Score: 93/100 (GOOD). This profile has not yet been claimed by the site owner.

University of Pennsylvania (Site 1031), 3400 Spruce Street has participated in 1 clinical trials.

Therapeutic areas: Coronavirus, Covid19.

Sponsors: National Institute of Allergy and Infectious Diseases (NIAID).

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Philadelphia

Browse all research sites in Pennsylvania · View every site in Philadelphia

Sponsor Feasibility Report

Trust Score: 93/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Pennsylvania (Site 1031), 3400 Spruce Street?

University of Pennsylvania (Site 1031), 3400 Spruce Street has a Crixeo Trust Score of 93/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Pennsylvania (Site 1031), 3400 Spruce Street conducted?

University of Pennsylvania (Site 1031), 3400 Spruce Street has 1 clinical trials on record. Their work covers Coronavirus, Covid19.

Is University of Pennsylvania (Site 1031), 3400 Spruce Street accredited by Crixeo Clinical Trials?

University of Pennsylvania (Site 1031), 3400 Spruce Street has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Pennsylvania (Site 1031), 3400 Spruce Street?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.